Study wrapper · #1082
Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.
Pisani D, Lorenza D, Fordellone M, et al. Endocrine. 2026.
DOI: 10.1007/s12020-026-04701-9PubMed: 42536323
Editor's note
Semaglutide and tirzepatide are among the class members pooled here, but the analysis reports a class-level estimate rather than peptide-specific results. The pooled odds ratio was non-significant and the constituent studies conflicted, so the finding is best regarded as inconclusive. Larger prospective studies are needed before drawing conclusions about pregnancy risk.
Plain-language abstract
This meta-analysis of three cohort studies (10,880 pregnancies) found no statistically significant association between GLP-1 receptor agonist exposure around conception or early pregnancy and hypertensive disorders of pregnancy. The evidence base was small and the individual studies disagreed in direction.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026